PNC Financial Services Group’s Oruka Therapeutics ORKA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$482K Buy
5,790
+1,565
+37% +$147K ﹤0.01% 1850
2026
Q2
$402K Buy
4,225
+1,039
+33% +$69.2K ﹤0.01% 1955
2026
Q1
$156K Buy
3,186
+1,736
+120% +$60.3K ﹤0.01% 2502
2025
Q4
$44K Sell
1,450
-564
-28% -$15.7K ﹤0.01% 3285
2025
Q3
$38.7K Buy
+2,014
New +$29.9K ﹤0.01% 3339
2023
Q3
– Sell
-42
Closed -$1.02K – 4782
2023
Q2
$1.02K Buy
+42
New +$1.03K ﹤0.01% 4509

Other funds holding ORKA

PNC Financial Services Group's ORKA Position: Q3 2026 in Review

PNC Financial Services Group increased its Oruka Therapeutics (ORKA) stake by 37% in Q3 2026, buying an estimated $147K and bringing the position to 5,790 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

PNC Financial Services Group first reported a position in ORKA in Q2 2023 and has held it in 6 quarters since. 259 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • PNC Financial Services Group held 5,790 shares of Oruka Therapeutics worth $482K as of Q3 2026.
  • PNC Financial Services Group bought 1,565 Oruka Therapeutics shares in Q3 2026, an estimated $147K.
  • Oruka Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #1850 holding.
  • PNC Financial Services Group first reported a position in Oruka Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 259 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.